Introduction {#s1}
============

The building of intricate neural networks during development is controlled by highly coordinated patterning programs that regulate the generation of different neuronal types in the correct number, place and time. The sequential production of different neuronal types from individual progenitors, *i.e.* temporal patterning, is a conserved feature of neurogenesis ([@bib9]; [@bib25]; [@bib34]; [@bib49]). For instance, individual radial glia progenitors in the vertebrate cortex sequentially give rise to neurons that occupy the different cortical layers in an inside-out manner ([@bib22]; [@bib48]). In *Drosophila*, neural progenitors (called neuroblasts) also give rise to different neuronal types sequentially. For example, projection neurons in the antennal lobe are born in a stereotyped temporal order and innervate specific glomeruli ([@bib29]; [@bib32]; [@bib85]). In both of these examples, individual progenitors age concomitantly with the developing animal (e.g., from embryonic stages 11--17 in mouse and from the first larval stage (L1) to the end of the final larva stage (L3) in *Drosophila*). Thus, these progenitors are exposed to changing environments that could alter their neuronal output. Indeed, classic heterochronic transplantation experiments demonstrated that young cortical progenitors placed in an old host environment alter their output to match the host environment and produce upper-layer neurons ([@bib17]; [@bib53]; [@bib54]).

The adult *Drosophila* central brain is built from \~100 neuroblasts ([@bib42]; [@bib77]; [@bib80]; [@bib86]) that divide continuously from L1 to L3 ([@bib26]; [@bib67]; [@bib84]). Each asymmetric division regenerates the neuroblast and produces an intermediate progenitor called ganglion mother cell (GMC) that divides only once, typically producing two different cell types ([@bib44]; [@bib68]; [@bib74]). Thus, during larval life central brain neuroblasts divide 50--60 times, sequentially producing many different neuronal types. All central brain neuroblasts progress through opposing temporal gradients of two RNA-binding proteins as they age: IGF-II mRNA binding protein (Imp) when they are young and Syncrip (Syp) when they are old ([@bib45]; [@bib70]; [@bib69]; [@bib83]). Loss of Imp or Syp in antennal lobe or Type II neuroblasts affects the ratio of young to old neuronal types ([@bib45]; [@bib59]). Imp and Syp also affect neuroblast lifespan ([@bib84]). Thus, a single temporal program can affect both the diversity of neuronal types produced and their numbers.

Since central brain neuroblasts produce different neuronal types through developmental time, roles for extrinsic cues have recently garnered attention. Ecdysone triggers all the major developmental transitions including progression into the different larval stages and entry in pupation ([@bib82]). The majority of central brain neuroblasts are not responsive to ecdysone until mid-larval life when they begin to express the Ecdysone Receptor (EcR) ([@bib69]). Expressing a dominant-negative version of EcR (EcR-DN) in Type II neuroblasts delays the Imp to Syp transition that normally occurs \~60 hr after larval hatching (ALH). This leads to many more cells that express the early-born marker gene Repo and fewer cells that express the late-born marker gene Bsh.

To further understand how extrinsic signals contribute to temporal patterning, we studied *Drosophila* mushroom body neuroblasts because of the deep understanding of their development. The mushroom body is comprised of \~2000 neurons (Kenyon cells) that belong to only three main neuronal types that have unique morphologies and play distinct roles in learning and memory ([@bib12]; [@bib28]; [@bib40]). They receive input mainly from \~200 projection neurons that each relays odor information from olfactory receptor neurons ([@bib78]). Each projection neuron connects to a random subset of Kenyon cells and each Kenyon cell receives input from \~7 different projection neurons ([@bib30]; [@bib55]; [@bib75]). This connectivity pattern requires a large number of mushroom body neurons (\~2,000) to represent complex odors ([@bib24]). To produce this very large number of neurons, mushroom body development is unique in many respects. Mushroom body neurons are born from four identical neuroblasts that divide continuously (unlike any other neuroblast) from the late embryonic stages until the end of pupation (\~9 days for \~250 divisions each) ([Figure 1A](#fig1){ref-type="fig"}; [@bib28]; [@bib36]; [@bib38]; [@bib39]; [@bib40]; [@bib57]; [@bib65]; [@bib66]). Furthermore, the two neurons born from each mushroom body GMC are identical. The neuronal simplicity of the adult mushroom body makes it ideal to study how extrinsic cues might affect diversity since the loss of any single neuronal type is obvious given that each is represented hundreds of times.

![α'β' neurons are not generated from *babo* mutant neuroblasts.\
(**A**) Summary of intrinsic temporal patterning mechanism operating during mushroom body development. During early larval stages, mushroom body neuroblasts express high levels of Imp (red) and Chinmo (red) in neurons to specify γ identity for \~85 neuroblast divisions (red-dashed box). From mid-L3 to metamorphosis, when Imp and Syp (cyan) are both at low levels, the same neuroblast divides \~40 times to produce α'β' neurons (magenta-dashed box). Low Chinmo regulates the expression Mamo, a terminal selector of α'β' identity. From the beginning of metamorphosis throughout pupal development, high Syp leads to αβ neurons (cyan-dashed outline). (**B**) Known molecular markers can distinguish between the three mushroom body neuronal types in the adult. (**C**) Mushroom body projections originating from neurons born from four neuroblasts (numbered 1 to 4) per hemisphere fasciculate into a single bundle (peduncle) before branching into the five mushroom body lobes. The first-born γ neurons (red) remodel during development to project into a single, medial lobe in the adult. This lobe is the most anterior of the medial lobes. Axons from α'β' neurons (magenta) bifurcate to project into the vertical and medial α' and β' lobes. The β' lobe is posterior to the γ lobe. The last-born αβ neurons (cyan) also bifurcate their axons into the vertical projecting α lobe and medial projecting β lobe. The α lobe is positioned adjacent and medial to the α' lobe. The β lobe is the most posterior medial lobe. (**D-E**) Representative max projections showing adult axons of clonally related neurons born from L1 stage in wildtype and *babo* conditions. *UAS-CD8::GFP* is driven by *mb-Gal4* (*OK107-Gal4*). Outlines mark GFP^+^ axons, where γ axons are outlined in red, α'β' axons are outlined in magenta, and αβ axons are outlined in cyan. A white box outlines the Inset panel. Trio (magenta) is used to label all γ and α'β' axons for comparison to GFP^+^ axons. (**D**) In wildtype, GFP^+^ axons (green, outlined in red, magenta and cyan) are visible in all observable mushroom body lobes. (**E**) In *babo* mutant clones, γ neurons (red outline) remain unpruned. GFP^+^ axons are missing inside the Trio^+^ α' lobe, indicating the absence of α'β' neurons. (**F-G**) Representative, single z-slices from the adult cell body region of clones induced at L1 in wildtype and *babo* conditions. *UAS-CD8::GFP* is driven by *mb-Gal4*. (**F**) Wildtype clones show the presence of strongly expressing Trio (magenta) and Mamo (blue, gray in single channel) neurons, indicative of α'β' identity. (**G**) In *babo* mutant clones, cells strongly expressing Trio and Mamo are not present. (**H**) Quantification of MARCM clones marked by *mb-Gal4*, which labels all mushroom body neuronal types. The number of α'β' neurons are quantified in wildtype (n = 7) and *babo* (n = 8) conditions. Plotted is the percentage of strong Mamo^+^ and GFP^+^ cells (clonal cells) versus all Mamo^+^ cells (clonal and non-clonal cells) within a single mushroom body. In wildtype, 25.5 ± 0.7% of the total strong Mamo expressing cells (α'β' neurons) are within clones, consistent with our expectation since each mushroom body is made from four neuroblasts. In *babo* clones, only 2.2 ± 0.4% of α'β' neurons are within clones. (**H'**) There are no significant differences between the average clone sizes (wildtype:533.6 ± 33.3; *babo*:551.3 ± 17.6). (**I**) Quantification of γ neurons marked by *γ-Gal4* (*R71G10-Gal4*) in MARCM clones. Plotted is the total number of γ neurons marked by GFP and Trio in wildtype (n = 10) and *babo* mutant (n = 12) clones. In wildtype, the average number of γ neurons is 154.3 ± 11.4. In *babo* mutants, the average is 178.4 ± 11.9. (**J**) Quantification of α'β' neurons marked by *α'β'-Gal4* (*R41C07-Gal4*) in MARCM clones. Plotted is the total number of α'β' neurons marked by GFP and strong Trio in wildtype (n = 4) and *babo* mutant (n = 8) clones. In wildtype, the average number of α'β' neurons is 81.5 ± 3.4. In *babo* mutants, the average is 2.1 ± 0.5. (**K**) Quantification of αβ neurons marked by *αβ-Gal4* (*R44E04-Gal4*) in MARCM clones. Plotted is the total number of GFP^+^ cells in wildtype (n = 7) and *babo* mutant (n = 8) clones. In wildtype, the average number is 276 ± 9.1. In *babo* mutants, the average number is 228.9 ± 13.2. A two-sample, two-tailed t-test was performed. \*\*\*p\<0.001, \*\*p\<0.01, ns: not significant. Scale bars: D, 20 µm; F, 5 µm.\
Figure 1---source data 1.Neuron number counts for data presented in [Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.](elife-58880-fig1){#fig1}

The three main neuronal types that make up the adult mushroom body are produced sequentially during neurogenesis: first γ, followed by α'β', and then αβ neurons ([@bib40]; [Figure 1A](#fig1){ref-type="fig"}), representing the simplest lineage in the central brain. The γ temporal window extends from L1 (the first larval stage) until mid-L3 (the final larval stage) when animals attain critical weight and are committed to metamorphosis; the α'β' window from mid-L3 to the beginning of pupation, and the αβ window from pupation until eclosion (the end of development). Like all other central brain neuroblasts Imp and Syp are expressed by mushroom body neuroblasts, but in much shallower gradients through time, which accounts for their extended lifespan ([@bib45]; [@bib84]). Imp and Syp are inherited by newborn neurons where they instruct temporal identity. Imp positively and Syp negatively regulate the translation of *chronologically inappropriate morphogenesis* (*chinmo*), a gene encoding a transcription factor that acts as a temporal morphogen in neurons ([@bib32]; [@bib59]; [@bib90]). The first-born γ neurons are produced for the first \~85 cell divisions, when Imp levels in neuroblasts, and thus Chinmo in neurons, are high. α'β' neurons are produced for the next \~40 divisions, when Imp and Syp are at similar low levels that translate into lower Chinmo levels in neurons. Low Chinmo then regulates the expression in neurons of *maternal gene required for meiosis* (*mamo*), which encodes a transcription factor that specifies the α'β' fate and whose mRNA is stabilized by Syp ([@bib46]). αβ neurons are generated for the final \~125 neuroblast divisions, when Syp levels are high, Imp is absent in neuroblasts, and thus Chinmo and Mamo are no longer expressed in neurons.

Extrinsic cues are known to have important roles in regulating neuronal differentiation during mushroom body neurogenesis. The ecdysone peak that controls entry into pupation regulates γ neuron axonal remodeling ([@bib41]). Ecdysone was also proposed to be required for the final differentiation of α'β' neurons ([@bib50]). EcR expression in γ neurons is timed by activin signaling, a member of the TGFβ family, from local glia ([@bib5]; [@bib89]). Activin signaling from glia is also required for the α'β' fate ([@bib51]): Knocking-down the activin pathway receptor Baboon (Babo) leads to the loss of α'β' neurons. It was proposed that activin signaling in mushroom body neuroblasts regulates the expression of EcR in prospective α'β' neurons and that when the activin pathway is inhibited, it leads to the transformation of α'β' neurons into later-born pioneer-αβ neurons (a subclass of the αβ class) ([@bib51]).

Although there is strong evidence that extrinsic cues have important functions in neuronal patterning in the *Drosophila* central brain, it remains unknown how extrinsic temporal cues interface with the Imp and Syp intrinsic temporal program to regulate neuronal specification. Here we address this question using the developing mushroom bodies. We independently discovered that activin signaling from glia is required for α'β' specification. However, we show that activin signaling lowers the levels of the intrinsic factor Imp in mushroom body neuroblasts to define the mid-α'β' temporal identity window. Removing the activin receptor Babo in mutant clones leads to the loss of α'β' neurons, to fewer last-born αβ neurons, and to the likely generation of additional first-born γ neurons without affecting overall clone size. This appears to be caused by a delayed decrease in Imp levels, although the intrinsic temporal clock still progresses even in the absence of activin signaling. We also demonstrate that ecdysone signaling is not necessary for the specification of α'β' neurons, although it might still be involved in later α'β' differentiation. Our results provide a model for how intrinsic and extrinsic temporal programs operate within individual progenitors to regulate neuronal specification.

Results {#s2}
=======

α'β' neurons are not generated from *babo* mutant neuroblasts {#s2-1}
-------------------------------------------------------------

The production of the three different mushroom body neuronal types occurs within specific developmental stages of larval and pupal development. That is, the γ window extends from L1 to mid-L3, the α'β' window from mid-L3 to pupation, and the αβ window from pupation to eclosion ([Figure 1A](#fig1){ref-type="fig"}; [@bib40]). This means that extrinsic cues could play a role in controlling or fine-tuning transitions between these temporal windows. Additionally, the specification of neuronal identity within each temporal window could be aided by extrinsic cues. To test these hypotheses, we used Mosaic Analysis with a Repressible Cell Marker (MARCM) ([@bib43]) to test the function of receptors for inter-cellular signaling pathways with known roles either in mushroom body neurogenesis (Activin and Ecdysone) ([@bib41]; [@bib50]; [@bib51]; [@bib89]) or more broadly during nervous system development (Hedgehog and juvenile hormone) ([Figure 1---figure supplement 1A--H](#fig1s1){ref-type="fig"}; [@bib6]; [@bib10]). We induced mushroom body neuroblast clones at L1 and compared the axonal morphologies of adult neurons born from mutant neuroblasts to neurons born from surrounding wildtype neuroblasts. To identify mushroom body axonal lobes (both mutant and wildtype), we used antibodies to the Rho guanine exchange factor Trio (a weak γ and strong α'β' cytoplasmic marker) and to the cell adhesion molecule Fasciclin II (FasII) (an axonal γ and αβ marker) ([Figure 1B](#fig1){ref-type="fig"}; [@bib4]; [@bib14]). To visualize mushroom body neurons within clones we expressed *UAS-CD8::GFP* under the control of *OK107-Gal4* (referred to as *mb-Gal4* hereafter), a *Gal4* enhancer trap in *eyeless* and a common mushroom body *Gal4* driver that strongly labels all mushroom body neuronal types during development and in the adult, and weakly mushroom body neuroblasts and young neurons throughout development ([@bib13]; [@bib45]; [@bib90]).

In wildtype clones induced at L1, GFP^+^ axons projected to all five mushroom body lobes: α, α΄, β, β' (hidden behind the γ lobe in max projections), and γ ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). In clones mutant for *babo,* we did not detect GFP^+^ axons within the α'β' lobes, which remained visible by Trio staining due to the presence of wildtype α'β' neurons ([Figure 1E](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). In addition, and as previously described, γ neurons within *babo* mutant clones remained unpruned (visualized by vertical GFP^+^ axons that were Trio^+^ and FasII^+^), providing a positive control since γ remodeling is known to require activin signaling ([Figure 1E](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}; [@bib5]; [@bib87]; [@bib89]).

Babo is the sole Type I receptor in the activin pathway (a member of the TGFβ family of signaling molecules). Babo with its Type II co-receptors binds four different activin ligands and acts through the transcription factor Smad on X (Smad2) ([@bib8]; [@bib76]). We induced *Smad2* mutant clones at L1 and characterized adult axonal morphologies. Similar to *babo* mutant clones, *Smad2* clones were missing α'β' neurons and also contained unpruned γ neurons ([Figure 1---figure supplement 1I](#fig1s1){ref-type="fig"}).

The absence of GFP^+^ axons within the α'β' lobes in *babo* mutant clones could be due to the loss of axonal projections, or to the loss of neuronal identity. Using antibodies against Trio and Mamo that strongly label α'β' neuron cell bodies in the adult ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1J](#fig1s1){ref-type="fig"}; [@bib2]; [@bib4]; [@bib15]; [@bib46]), we detected strong Trio^+^ and Mamo^+^ cells within adult GFP^+^ clones induced at L1 ([Figure 1F](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1K](#fig1s1){ref-type="fig"}). In *babo* mutant clones however, the vast majority of strong Trio^+^ and Mamo^+^ cells inside clones were missing compared to surrounding wildtype neurons ([Figure 1G](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1L](#fig1s1){ref-type="fig"}), suggesting that α'β' neurons were not specified. We quantified the number of α'β' neurons in wildtype and *babo* clones by counting the number of strong Mamo^+^ cells within a clone versus the total number of strong Mamo^+^ cells outside the clone. In wildtype MARCM clones affecting a single mushroom body neuroblast (n = 7), the percentage of all α'β' neurons that were present within the clones was 25.5 ± 0.7%, the expected ratio since each mushroom body is built from four identical neuroblasts ([Figure 1H](#fig1){ref-type="fig"}; [@bib28]; [@bib40]). In comparison, in *babo* mutant clones (n = 8) the percentage of α'β' neurons within clones was 2.2 ± 0.4% ([Figure 1H](#fig1){ref-type="fig"}). Interestingly, although there was a decrease in the number of adult α'β' neurons upon expression of *UAS-babo-RNAi* with *mb-Gal4*, the majority of α'β' neurons were not lost ([Figure 1---figure supplement 1M--Q](#fig1s1){ref-type="fig"}). Importantly, γ neurons in these brains did not remodel ([Figure 1---figure supplement 1P--P'''](#fig1s1){ref-type="fig"}), indicating that the *babo-RNAi* worked efficiently. This difference with *babo* clones is likely due to the weak expression of *mb-Gal4* in neuroblasts and newborn neurons and suggested to us that activin signaling is necessary for α'β' specification by acting in neuroblasts (see below).

We next sought to determine the fate of the missing α'β' neurons in *babo* clones, particularly since there was no significant difference in average clone sizes between mutant and control clones labeled with *mb-Gal4* (wildtype: clone size = 533.6 ± 33.3, n = 7; *babo*: clone size = 551.3 ± 17.6, n = 7) ([Figure 1H'](#fig1){ref-type="fig"}), which suggests that there is no defect in neuroblast proliferation, and that α'β' neurons are not lost by cell death in *babo* clones. However, to directly test whether cell death played a role, we expressed the caspase inhibitor P35 in *babo* mutant clones ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). However, α'β' neurons were still missing in the adult ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}), indicating that α'β' neurons are not generated and then die. We thus tested whether the γ or αβ temporal windows were extended in *babo* mutant clones. We made MARCM clones in which the γ, α'β' or αβ neurons were specifically marked with different *Gal4* lines, and then quantified the total number of GFP^+^ neurons in wildtype versus *babo* mutant clones ([Figure 1I--K](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2B--M](#fig1s2){ref-type="fig"}). Using *R71G10-Gal4* ([@bib27]) (referred to as *γ-Gal4*), the average number of γ neurons trended higher in *babo* mutant clones, although not significantly (wildtype: 154.3 ± 11.4, n = 10; *babo*: 178.4 ± 11.9, n = 12) ([Figure 1I](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2B--E](#fig1s2){ref-type="fig"}), likely because the number of γ neurons directly depends on the time of clone induction. α'β' neurons, marked by *R41C07-Gal4* (referred to as *α'β'-Gal4*), were mostly missing in *babo* mutant clones compared to wildtype clones (wildtype: 81.5 ± 3.6, n = 4; *babo*: 2.1 ± 0.5, n = 8,) consistent with our previous results when counting strong Mamo^+^ cells in *babo* clones marked by *mb-Gal4* ([Figure 1H](#fig1){ref-type="fig"}, [Figure 1J](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2F--I](#fig1s2){ref-type="fig"}). The average number of αβ neurons, marked by *R44E04-Gal4* (referred to as *αβ-Gal4*), was significantly reduced in *babo* versus wildtype clones (wildtype: 276 ± 9.1, n = 7,; *babo*: 228.9 ± 13.2, n = 8) ([Figure 1K](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2J--M](#fig1s2){ref-type="fig"}). Together, these results suggest that additional γ neurons are likely produced, and that fewer αβ neurons are generated, in *babo* mutant clones. Although this might appear to contradict a recent report that showed that a subclass of αβ neurons (pioneer-αβ) increases ([@bib51]), it is likely that the earliest born pioneer-αβ are increased because of the delayed decrease in the Imp gradient, but that the later-born αβ neurons do not have time to form (see below and Discussion). We note that the total number of neurons labeled by our neuron type specific *Gal4* drivers did not add up to the expected number of \~500 neurons in *babo* mutant clones, which is likely explained by the large variability in the number of γ neurons labeled by *γ-Gal4*. Next, we focused on understanding whether and how activin signaling interacts with the intrinsic Imp and Syp temporal program.

Activin signaling acts in neuroblasts to lower Imp levels and specify α'β' neurons {#s2-2}
----------------------------------------------------------------------------------

Given that α'β' neuronal specification is intrinsically controlled by Imp and Syp ([@bib45]), we asked whether activin signaling acts through or in parallel to this intrinsic temporal system, specifically at L3 when α'β' neurons are being produced. We first asked whether *babo* is expressed at L3 in mushroom body neuroblasts. Based on published transcriptome data collected from mushroom body neuroblasts at different developmental stages ([@bib45]; [@bib83]), *babo* is expressed evenly through time in mushroom body neuroblasts, unlike the two RNA binding proteins *Imp* and *Syp* ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Although this measure does not take into account the possibility of post-transcriptional regulation, it is likely that the activin signaling pathway is temporally controlled by ligand interaction and not by differential expression of *babo*.

To directly test whether activin signaling acts on Imp and Syp to affect α'β' specification, we induced MARCM clones for *babo* at L1 and compared the Imp to Syp protein ratio in mutant mushroom body neuroblasts to surrounding wildtype neuroblasts at wandering L3 ([Figure 2](#fig2){ref-type="fig"}). The average Imp to Syp ratio was significantly higher in *babo* neuroblasts (ratio: 4.2 ± 0.4; n = 9 from 4 different brains) compared to wildtype neuroblasts (ratio: 2.4 ± 0.2; n = 23 from the same 4 brains as *babo*) at L3, driven by a significantly higher Imp level in mutant neuroblasts ([Figure 2](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}) while Syp was not significantly different ([Figure 2---figure supplement 1B'](#fig2s1){ref-type="fig"}). In addition, the α'β' neuronal marker Mamo ([@bib46]) was lost in *babo* mutant clones at L3 while the level of Chinmo was higher in these neurons ([Figure 2---figure supplement 1C--C'''](#fig2s1){ref-type="fig"}), consistent with the notion that high Imp levels block α'β' specification through maintained higher levels of Chinmo that likely lead to the increased production of γ neurons. The significantly higher Imp to Syp ratio in *babo* mutant neuroblasts persisted even \~24 hr After Pupal Formation (APF) (*babo* ratio: 0.58 ± 0.11; n = 7 from 6 different brains; wildtype ratio: 0.27 ±. 02; n = 27 from the same 6 brains as *babo*), once again driven by higher Imp levels ([Figure 2---figure supplement 1D--I](#fig2s1){ref-type="fig"}). Together, these results indicate that activin signaling lowers Imp levels at late larval and early pupal stages. Importantly, although Imp was higher in *babo* mutant neuroblasts and persisted longer, the absolute level of Imp still decreased significantly albeit with prolonged kinetics, while the absolute level of Syp was higher in *babo* mutant neuroblasts at \~24 hr APF vs. L3 ([Figure 2---figure supplement 1J--J'](#fig2s1){ref-type="fig"}): Thus, these changes are either intrinsically regulated or are affected by additional extrinsic factors. Our finding that Imp and Chinmo were higher in *babo* mutant neuroblasts and neurons at L3 is also consistent with our suggestion that additional γ neurons are produced during the α'β' time window. The lack of α'β' neurons in *babo* mutant clones even though Imp levels were finally low at \~24 hr APF suggests that α'β' specification may only occur from L3 to the start of pupation.

![Activin signaling acts in neuroblasts to lower Imp levels.\
(**A**) Representative image of a *babo* mushroom body neuroblast marked by *UAS-CD8::GFP* driven by *mb-Gal4* (red box) adjacent to a wildtype neuroblast (green-dashed box) in the same focal plane from a wandering L3 stage brain, immunostained for Imp (blue, gray in single channel) and Syp (magenta). (**B**) Close-up view of wildtype neuroblast (green-dashed box in A). (**C**) Close up view of *babo* mutant neuroblast (red box in A). (**D**) Quantification of the Imp to Syp ratio in *babo* neuroblasts (4.2 ± 0.4, n = 9 from 4 different brains) compared to wildtype (2.4 ± 0.3, n = 23 from the same 4 brains as *babo* neuroblasts). A two-sample, two-tailed t-test was performed. \*\*\*p\<0.001, ns: not significant. Scale bar: 10 µm.\
Figure 2---source data 1.Imp and Syp fluorescence quantification in *babo *mutant clones.](elife-58880-fig2){#fig2}

We have shown that activin signaling functions in mushroom body neuroblasts to decrease Imp during L3. However, previous studies have shown that Babo also acts post-mitotically in mushroom body γ neurons where it times the expression of EcR for their remodeling, indicating that Babo can act independently in neuroblasts and in neurons ([@bib89]). To test if activin signaling functions post-mitotically in prospective α'β' neurons, we characterized the morphology of *babo* mutant neurons born from ganglion mother cell (GMC) clones induced during mid-late L3, the time at which α'β' neurons are born. GMCs are intermediate progenitors that divide only once to produce two neurons. In this way, the role of Babo in prospective α'β' neurons can be tested without affecting mushroom body neuroblasts: α'β' neurons were present in *babo* GMC clones (n = 34/34), observable by axonal projections into the Trio labeled α'β' lobes ([Figure 2---figure supplement 1K--K'](#fig2s1){ref-type="fig"}). As a positive control for the efficiency of *babo* GMC clones, we also made *babo* GMC clones at L1 to target γ neurons. In the majority of cases, γ axons remained unpruned (n = 8/10, [Figure 2---figure supplement 1L--L'](#fig2s1){ref-type="fig"}; [@bib89]). These results show that activin signaling acts in mushroom body neuroblasts, and not in neurons, to specify the α'β' fate.

Activin signaling is sufficient to expand production of α'β' neurons {#s2-3}
--------------------------------------------------------------------

Since activin signaling functions in mushroom body neuroblasts and is necessary for α'β' specification, we next investigated whether it is sufficient for the α'β' fate. We expressed a constitutively active form of the Babo receptor (*UAS-Babo-Act*) throughout development in MARCM clones with *mb-Gal4* and assessed the total number of α'β' neurons in the adult by strong Mamo expression. While in wildtype clones the percentage of α'β' neurons was 25.5 ± 0.7% (n = 7), the number of α'β' neurons present within *UAS-Babo-Act* clones significantly increased to 32 ± 1.4% (n = 4) ([Figure 3A--B](#fig3){ref-type="fig"}). To ask when these additional α'β' neurons were produced, we characterized the expression of the α'β' marker Mamo in young neurons at early L3, when γ neurons are being produced. In comparison to adjacent wildtype neurons, Mamo was expressed in neurons in *UAS-Babo-Act* clones at this stage ([Figure 3C--D](#fig3){ref-type="fig"}). These results confirm the precocious specification of α'β' neurons, likely at the expense of γ neurons (which would normally be produced at this stage). Importantly, constitutively expressing an activated version of Babo did not result in adult clones consisting entirely of α'β' neurons, highlighting that activin signaling alone is not master regulator of the α'β' fate and that other components are necessary to specify this neuronal type.

![Activin signaling is sufficient to expand production of α'β' neurons.\
(**A**) Expression of *UAS-Babo-Act* by *mb-Gal4* leads to additional α'β' neurons but does not convert all mushroom body neurons into this fate. (**B**) Plotted is the percentage of strong Mamo^+^ and GFP^+^ cells (clonal cells) versus all Mamo^+^ cells (clonal and non-clonal cells) within a single mushroom body. The number of α'β' neurons is quantified in wildtype (n = 7, replotted from data in [Figure 1H](#fig1){ref-type="fig"}) and *UAS-babo-Act* (n = 4). In wildtype, 25.5 ± 0.7% of the total strong Mamo expressing cells (α'β' neurons) are within a clone while precociously activating the activin pathway increased the percentage to 32 ± 1.4%. (**C**) A representative image of an early L3 brain in which a single mushroom body neuroblast is expressing *UAS-babo-Act* driven by *mb-Gal4* (white-dashed line). Imp (blue) and Syp (magenta), along with GFP (green), are used to identify mushroom body neuroblasts (asterisks) and neurons. (**D**) Inset (gray box in C) showing that Mamo (gray) is expressed inside GFP^+^ cells that express *UAS-babo-Act* but not outside in adjacent wildtype mushroom body neurons (yellow line) (n = 3/3). A two-sample, two-tailed t-test was performed. \*\*\*p\<0.001.\
Figure 3---source data 1.Neuron number counts for data presented in [Figure 3](#fig3){ref-type="fig"}.](elife-58880-fig3){#fig3}

Glia are the source of the activin ligand Myoglianin to specify α'β' neurons {#s2-4}
----------------------------------------------------------------------------

Our finding that activin signaling plays an important role in specifying α'β' identity during mushroom body development led us to question from where the activin ligand originates. Glia secrete the activin ligand Myoglianin (Myo) to initiate γ neuron remodeling by activating EcR at L3 ([@bib5]; [@bib87]). Therefore, we hypothesized that Myo from glia may also regulate α'β' specification. To test this, we knocked-down *myo* by expressing *UAS-myo-RNAi* with *repo-Gal4*, a driver expressed in all glia, and quantified the total number of α'β' neurons based on strong Mamo expression in the adult ([Figure 4A--E](#fig4){ref-type="fig"}). In comparison to control (428.9 ± 16.2, n = 10), the number of α'β' neurons was dramatically reduced (106.6 ± 11.4; n = 10) ([Figure 4E](#fig4){ref-type="fig"}). Mamo was also not expressed in mushroom body neurons at L3 ([Figure 4F--G](#fig4){ref-type="fig"}). Importantly, EcR was not expressed in γ neurons at this stage, providing a positive control for the efficiency of *UAS-myo-RNAi* ([@bib5]). We note that even though the number of α'β' neurons was reduced in this experiment, *myo* knockdown was weaker than *babo* mutant clones, possibly due to incomplete knockdown of *myo* or because more than one ligand (or more than one source) contribute to α'β' specification (see Discussion). Our results are consistent with a recent report that also showed that glia are the source of Myo for α'β' specification ([@bib51]).

![Glia are the source of the activin ligand Myo to specify α'β' neurons.\
(**A-B**) Representative images of adult mushroom body lobes labeled by FasII (green) and Trio (magenta). (**A**) In wildtype controls (428.9 ± 16.2, n = 10) (*repo-Gal4* only) all three neuronal types are present based on axonal projections. (**B**) Expressing *UAS-myo-RNAi* (106.6 ± 11.4, n = 10) causes γ neurons not to remodel and to the loss of the majority of α'β' neurons, however some still remain (purple arrow, FasII- region). (**C-D**) Representative images of adult mushroom body cell body region. Trio (magenta) and Mamo (gray) are used to distinguish between the three neuronal types. Expressing *UAS-myo-RNAi* leads to loss of the majority of strong Mamo+ and Trio^+^ cells, indicating the loss of α'β' neurons. (**E**) Quantification of phenotypes presented in **A-D**. (**F**) At L3, EcR (magenta) and Mamo (gray) are expressed in mushroom body neurons labeled by Eyeless (green, yellow outline). Mamo^+^ cells are newborn α'β' neurons. G. Expressing *UAS-myo-RNAi* with *repo-Gal4* leads to loss of both Mamo and EcR in mushroom body neurons. A two-sample, two-tailed t-test was performed. \*\*\*p\<0.001.\
Figure 4---source data 1.Neuron number counts for data presented in [Figure 4](#fig4){ref-type="fig"}.](elife-58880-fig4){#fig4}

α'β' neurons are specified by low Imp levels at L3 {#s2-5}
--------------------------------------------------

We and others have shown that activin signaling is necessary for α'β' specification ([@bib51]). We have shown that activin signaling acts by lowering Imp levels at L3. Although Imp is required for α'β' specification ([Figure 5---figure supplement 1A--E](#fig5s1){ref-type="fig"}; [@bib45]), we wanted to determine whether low Imp levels are required at L3. We therefore characterized Mamo expression in young neurons at L3 following knockdown (*UAS-Imp-RNAi*) or overexpression (*UAS-Imp-OE*) of *Imp* with *mb-Gal4*. ([Figure 5A--C](#fig5){ref-type="fig"}; [@bib45]). Consistent with our model, Mamo was not expressed in either condition. In comparison, although knocking-down *Syp* by expressing *UAS-Syp-RNAi* led to the loss of Mamo, its early overexpression (*UAS-Syp-OE*) did not ([Figure 5D--E](#fig5){ref-type="fig"}). The loss of Mamo in *Syp* knockdown is consistent with its role in stabilizing *mamo* transcripts at L3 ([@bib46]). We conclude that low Imp and low or high Syp levels are required for α'β' specification. Consistent with this, we were unable to rescue the loss of α'β' neurons in *babo* mutant clones by constitutively repressing Imp with *UAS-Imp-RNAi* (0.2 ± 0.2%, n = 7) ([Figure 5---figure supplement 1I](#fig5s1){ref-type="fig"}, [Figure 5---figure supplement 1N](#fig5s1){ref-type="fig"}, [Figure 5---figure supplement 1P](#fig5s1){ref-type="fig"}), likely due Imp reduction below the threshold required for α'β' specification (see Discussion). However, we could rescue *babo* mutant clones by expressing *UAS-babo* (21.1 ± 2.4%, n = 6) ([Figure 5---figure supplement 1F--H](#fig5s1){ref-type="fig"}, [Figure 5---figure supplement 1K--M](#fig5s1){ref-type="fig"}, [Figure 5---figure supplement 1P](#fig5s1){ref-type="fig"}). Overexpressing Syp (*UAS-Syp-OE*) to reduce the altered Imp:Syp ratio in *babo* mutant clones also did not rescue α'β' neurons (1.8 ± 0.5%, n = 7) ([Figure 5---figure supplement 1J](#fig5s1){ref-type="fig"}, [Figure 5---figure supplement 1O--P](#fig5s1){ref-type="fig"}), further highlighting that Imp but not Syp levels are important for α'β' specification.

![α'β' neurons are specified by low Imp levels at L3.\
(**A-A'**) Representative image of wildtype mushroom body neurons labeled by *mb-Gal4* driving *UAS-CD8::GFP* (green, white-dashed outline) during the wandering L3 stage. Mamo (gray) is used as a marker for α'β' neurons. (**B-B'**) When *mb-Gal4* is used to drive *UAS-Imp-RNAi*, Mamo is not expressed. (**C-C'**) Similarly, Mamo expression is lost when overexpressing *Imp* (*UAS-Imp-overexpression* (*OE*)). (**D-D'**). Expressing *UAS-Syp-RNAi* also leads to the loss of Mamo. (**E**) Expressing *UAS-Syp-overexpression* (*OE*) does not affect Mamo. Scale bar: 5 µm.\
Figure 5---source data 1.Neuron number counts for data presented in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.](elife-58880-fig5){#fig5}

Ecdysone signaling is not necessary for α'β' specification {#s2-6}
----------------------------------------------------------

It has been proposed that activin signaling in mushroom body neuroblasts leads to EcR expression in neurons and that ecdysone signaling at late L3 induces differentiation of α'β' neurons ([@bib50]; [@bib51]). The role of ecdysone was tested by expressing a dominant-negative ecdysone receptor (*UAS-EcR-DN*). We confirmed these results by also expressing *UAS-EcR-DN* driven by *mb-Gal4* and were unable to detect GFP^+^ mutant axons within adult α'β' lobes marked by Trio ([Figure 6A--B](#fig6){ref-type="fig"}). In addition, strong Trio^+^ and Mamo^+^ cells were missing inside *UAS-EcR-DN* mutant clones compared to wildtype clones (wildtype: 25.5 ± 0.7%, n = 7; *UAS-EcR-DN*: 3.4 ± 0.6%, n = 6) ([Figure 6C--E](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1A--B](#fig6s1){ref-type="fig"}). However, we were surprised to find that α'β' neurons were still present in mutant clones for the EcR co-receptor *ultraspiracle* (*usp*) ([Figure 6F](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). Therefore, we sought to better understand how expressing *UAS-EcR-DN* blocks α'β' specification.

![Ecdysone signaling is not necessary for α'β' specification.\
(**A-B**) Representative max projections showing adult axons of clonally related neurons born from L1 stage in wildtype and *UAS-EcR-DN* conditions. *UAS-CD8::GFP* is driven by *mb-Gal4* (*OK107-Gal4*). Outlines mark GFP^+^ axons, where γ axons are outlined in red, α'β' axons are outlined in magenta, and αβ axons are outlined in cyan. A white box outlines the Inset panel. Trio (magenta) is used to label all γ and α'β' axons for comparison to GFP^+^ axons. (**A**) In wildtype, GFP^+^ axons are visible in all mushroom body lobes. (**B**) α'β' axons are lost, and γ neurons do not remodel, in *UAS-EcR-DN* expressing clones. (**C-D**) Representative, single z-slices from the adult cell body region of clones induced at L1 in wildtype and *UAS-EcR-DN* conditions. *UAS-CD8::GFP* is driven by *mb-Gal4*. (**C**) Wildtype clones show the presence of strongly expressing Trio (magenta) and Mamo (blue, gray in single channel) neurons, indicative of α'β' identity. (**D**) In *UAS-EcR-DN* clones, strong Trio and Mamo cells are not present. (**E**) Quantification of MARCM clones marked by *mb-Gal4*, which labels all mushroom body neuronal types. The number of α'β' neurons are quantified in wildtype (n = 7, replotted from data in [Figure 1H](#fig1){ref-type="fig"}) and *UAS-EcR-DN* (n = 6) conditions. Plotted is the percentage of strong Mamo^+^ and GFP^+^ cells (clonal cells) versus all Mamo^+^ cells (clonal and non-clonal cells) within a single mushroom body. In wildtype, 25.5 ± 0.7% of the total strong Mamo expressing cells (α'β' neurons) are within clones. In *UAS-EcR-DN* clones, only 3.4 ± 0.6% of α'β' neurons are within clones. (**F**) *usp* mutant clones contain α'β' neurons. FasII (magenta) is used to label γ and αβ lobes. Red arrow indicates unpruned γ neurons. (**G**) Representative image of an *UAS-EcR-DN* expressing neuroblast marked by *UAS-CD8::GFP* driven by *mb-Gal4* (red box) ventral to a wildtype neuroblast (green-dashed box) from the same wandering L3 stage brain, immunostained for Imp (blue, gray in single channel) and Syp (magenta). (**H**) Close-up view of wildtype neuroblast (green-dashed box in G). (**I**) Close-up view of *UAS-EcR-DN* neuroblast (red box in G). (**J**) Quantification of the Imp to Syp ratio in *UAS-EcR-DN* neuroblasts (n = 4 from four different brains) compared to wildtype (n = 27 from the same four brains as *UAS-EcR-DN* neuroblasts). (**K**) A representative adult mushroom body clone (green) induced at L1 expressing *UAS-EcR-DN* driven by *mb-Gal4*. α'β' neurons (GFP^+^ (green), FasII- (magenta)) are not observed and γ neurons do not remodel (GFP^+^, FasII^+^, red outline). (**L**) A representative adult wildtype clone induced at L1 driven by *NB + mb2-Gal4*. All three neuron types are present, including α'β' neurons (GFP^+^, FasII^-^, magenta outline). (**M**) α'β' neurons are also present when *UAS-EcR-DN* is driven by *NB + mb2-Gal4* although γ neurons do not remodel. (**N**) Quantification of MARCM clones in which *UAS-EcR-DN* is driven by *mb-Gal4* (n = 6, replotted from data in E) or *NB + mb2-Gal4* (n = 6) compared to wildtype (n = 7, replotted from data in [Figure 1H](#fig1){ref-type="fig"}). In *UAS-EcR-DN* clones driven by *NB + mb2-Gal4*, 24.6 ± 2.1% of α'β' neurons are within a clone, similar to wildtype. O. At L3, Mamo (gray) is expressed in young mushroom body neurons (α'β') while EcR (magenta) can only be detected in more mature neurons (mainly γ at this stage). Note that there is no overlap between Mamo and EcR. (**P**) Expressing *UAS-EcR-DN* with *mb-Gal4* (green, white outline) leads to the loss of Mamo expression (gray) inside the clone but not in surrounding wildtype mushroom body neurons. (**Q**) In contrast, expressing *UAS-EcR-RNAi* drivenE by *mb-Gal4* abolishes EcR expression but does not affect Mamo. For E and J a two-sample, two-tailed t-test was performed. For N, a Tukey test was performed. \*\*\*p\<0.001, ns: not significant. Scale bars: A, 20 µm; G, 10 µm; P, 5 µm.\
Figure 6---source data 1.Neuron number counts for data presented in [Figure 6](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}.\
Figure 6---source data 2.Imp and Syp fluorescence quantification when expressing *UAS-EcR-DN.*](elife-58880-fig6){#fig6}

First, unlike our result in *babo* mutant neuroblasts, we did not observe a significant difference in the average Imp to Syp protein ratio at L3 in *UAS-EcR-DN* expressing mushroom body neuroblasts with *mb-Gal4* (*UAS-EcR-DN* ratio: 2.6 ± 0.7, n = 4 from four different brains; wildtype ratio: 1.7 ± 0.3, n = 27 from the same four brains as *UAS-EcR-DN*) ([Figure 6G--J](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1D--D'](#fig6s1){ref-type="fig"}). Driving even stronger expression of *UAS-EcR-DN* in mushroom body neuroblasts with *inscuteable-Gal4* (referred to as *NB-Gal4*) and labeling all adult neurons with *R13F02-Gal4* (referred to as *mb2-Gal4*) ([@bib31]) also did not lead to the loss of α'β' neurons in the adult ([Figure 6K--N](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1E--F](#fig6s1){ref-type="fig"}). These results indicate that EcR-DN only blocks α'β' specification when expressed in newborn mushroom body neurons, not in neuroblasts.

Given these results, we next asked whether expressing *UAS-EcR-DN* affects Mamo during development, which labels newborn postmitotic α'β' neurons ([@bib46]); Mamo expression was lost in *UAS-EcR-DN* expressing clones driven by *mb-Gal4* ([Figure 6P](#fig6){ref-type="fig"}) but it was not affected by the expression of *UAS-EcR-RNAi* ([Figure 6Q](#fig6){ref-type="fig"}), although the RNAi was effective since we could not detect EcR protein in mushroom body neurons ([Figure 6O](#fig6){ref-type="fig"}, [Figure 6Q](#fig6){ref-type="fig"}). Given these contradictory results, we compared Mamo and EcR expression at L3. However, Mamo and EcR were mutually exclusive as EcR was not expressed in newborn α'β' neurons (see [Figure 6O''](#fig6){ref-type="fig"}), which precludes the possibility that EcR-DN inhibits EcR function in these neurons and might therefore act through off-target inhibition of Mamo. These results confirm the lack of EcR protein in mushroom body neuroblasts and young neurons at wandering L3 ([Figure 6---figure supplement 1G--H](#fig6s1){ref-type="fig"}), although EcR was clearly expressed in mature (mostly γ) neurons at this stage ([Figure 6---figure supplement 1H--H''](#fig6s1){ref-type="fig"}; [@bib41]; [@bib45]; [@bib50]). Finally, we were unable to rescue the loss of α'β' neurons in *babo* mutant clones by expressing *UAS-EcR-B1* ([Figure 6---figure supplement 1I--J](#fig6s1){ref-type="fig"}), consistent with the notion that EcR does not function in α'β' specification downstream of activin signaling (see Discussion). In summary, α'β' neurons were only lost in adult clones when expressing *UAS-EcR-DN* (with *mb-Gal4*) and not in *usp* mutant clones, and α'β' neurons were still present when expressing *EcR-RNAi* in L3. Most importantly, EcR protein was not detected in Mamo^+^ cells during development, although expressing *UAS-EcR-DN* blocked Mamo expression at L3. Thus, it is unlikely that ecdysone signaling is involved in α'β' specification although it might still be used later during α'β' differentiation ([@bib50]). We conclude that the loss of α'β' neurons when expressing *UAS-EcR-DN* is caused by artifactual inhibition of Mamo (see Discussion).

Discussion {#s3}
==========

Establishment of mushroom body neuronal identities {#s3-1}
--------------------------------------------------

Mushroom body neurogenesis is unique and programmed to generate many copies of a few neuronal types. During the early stages of mushroom body development, high Imp levels in mushroom body neuroblasts are inherited by newborn neurons and translated into high Chinmo levels to specify γ identity. As in other central brain neuroblasts, as development proceeds, inhibitory interactions between Imp and Syp help create a slow decrease of Imp and a corresponding increase of Syp. However, at the end of the γ temporal window (mid-L3), activin signaling from glia acts to rapidly reduce Imp levels in mushroom body neuroblasts without significantly affecting Syp, establishing a period of low Imp (and thus low Chinmo in neurons) and also low Syp. This is required for activating effector genes in prospective α'β' neurons, including Mamo, whose translation is promoted by Syp ([@bib46]). The production of αβ identity begins when Imp is further decreased and Syp levels are high during pupation (modeled in [Figure 7](#fig7){ref-type="fig"}). Low Chinmo in αβ neurons is also partly regulated by ecdysone signaling through the activation of *Let-7-C*, which targets *chinmo* for degradation ([@bib37]; [@bib81]). Based on our model, α'β' neurons could not be rescued by knocking-down Imp in *babo* clones ([Figure 5---figure supplement 1I,N,P](#fig5s1){ref-type="fig"}), since low Imp is required for α'β' specification while the knockdown reduces its level below this requirement. We might expect to rescue α'β' neurons if Imp levels were specifically reduced to the appropriate levels at L3. However, reducing Imp levels might not be the only function of activin signaling, which may explain why α'β' neurons are not simply made earlier (e.g., during L1-L2) when Imp is knocked-down.

![Model of how activin signaling defines the α'β' temporal identity window.\
In wildtype, as development proceeds, mushroom body neuroblasts incorporate an activin signal (Myo) from glia through Babo to lower the level of the intrinsic temporal factor Imp (magenta dashed line). The lower Imp levels inherited by newborn neurons leads to lower Chinmo levels to control the expression of the α'β' effector Mamo, defining the mid-temporal window (magenta dashed lines). In *babo* mutants, Imp remains higher for longer, leading to the loss of Mamo (and likely many other targets) during mid-late L3 in neurons. In this model, γ neuron numbers increase, α'β' neurons are lost, and fewer αβ neurons are produced. Nonetheless, the Imp to Syp transition still occurs, allowing for young (γ) and old (αβ) fates to be produced.](elife-58880-fig7){#fig7}

In *babo* mutant clones, we speculate that additional γ neurons are produced at the expense of α'β' neurons since Imp levels in neuroblasts (as well as Chinmo in neurons) are higher for a longer time during development; There was also a significant decrease in the total number of αβ neurons in *babo* mutant clones that contrasts with a recent report by Marchetti and Tavosanis that instead concluded that additional pioneer-αβ neurons are produced ([@bib51]). We believe that there is both an increase in the number of γ neurons and of the pioneer-αβ neuron subclass because pioneer-αβ neurons are the first of the αβ class to be specified (when Imp is still present at very low levels) during pupation. We speculate that pioneer-αβ neurons are produced during the extended low Imp window that we detect during pupation in *babo* clones. However, this does not leave the time for the remaining population of αβ neurons to be formed, which explains why their number is reduced.

In this study, we have focused on the three main classes of mushroom body neurons although at least seven subtypes exist: 2 γ, 2 α'β' and 3 αβ ([@bib3]; [@bib63]). The subtypes are specified sequentially ([@bib3]) suggesting that each of the three broad mushroom body temporal windows can be subdivided further, either by fine-scale reading of the changing Imp and Syp gradients, by additional extrinsic cues, or perhaps by a tTF series as in other neuroblasts.

Temporal patterning of *Drosophila* central brain neuroblasts {#s3-2}
-------------------------------------------------------------

Postembryonic central brain neuroblasts are long-lived and divide on average \~50 times. Unlike in other regions of the developing *Drosophila* brain, rapidly progressing series of tTFs have not yet been described in these neuroblasts ([@bib19]; [@bib25]; [@bib34]; [@bib60]). Instead, they express Imp and Syp in opposing temporal gradients ([@bib45]; [@bib59]; [@bib69]). Conceptually, how Imp and Syp gradients translate into different neuronal identities through time has been compared to how morphogen gradients pattern tissues in space ([@bib46]; [@bib45]). During patterning of the anterior-posterior axis of the *Drosophila* embryo, the anterior gradient of the Bicoid morphogen and the posterior Nanos gradient are converted into discrete spatial domains that define cell fates ([@bib7]; [@bib46]). Since gradients contain unlimited information, differences in Imp and Syp levels through time could translate into different neuronal types. Another intriguing possibility is that tTF series could act downstream of Imp and Syp, similarly to how the gap genes in the *Drosophila* embryo act downstream of the anterior-posterior morphogens. We have shown that another possibility is that temporal extrinsic cues can be incorporated by individual progenitors to increase neuronal diversity. In mushroom body neuroblasts activin signaling acts directly on the intrinsic program, effectively converting two broad temporal windows into three to help define an additional neuronal type. We propose that subdividing the broad Imp and Syp temporal windows by extrinsic cues may be a simple way to increase neuronal diversity in other central brain neuroblasts.

We have also shown that activin signaling times the Imp to Syp transition for mushroom body neuroblasts, similar to the function of ecdysone for other central brain neuroblasts ([@bib69]). In both cases however, the switch still occurs, indicating that a separate independent clock continues to tick. This role for extrinsic cues during *Drosophila* neurogenesis is reminiscent of their roles on individual vertebrate progenitors. For example, hindbrain neural stem cells progressively produce motor neurons followed by serotonergic neurons before switching to producing glia ([@bib11]; [@bib18]). The motor neuron to serotonergic neuron switch is fine-tuned by TGFβ signaling. It would be interesting to determine if hindbrain neuronal subtypes are lost in TGFβ mutants, similar to how α'β' identity is lost in the mushroom bodies in *babo* mutants.

Ecdysone signaling is not necessary for α'β' specification {#s3-3}
----------------------------------------------------------

The specification of α'β' neurons begins at mid-L3 with the onset of Mamo expression ([@bib46]). In contrast, high levels of EcR are detected in mature mushroom body neurons starting at late L3 ([@bib41]). At this stage, both γ and α'β' neurons already exist and new α'β' neurons are still being generated. Thus, Mamo expression precedes EcR expression. These non-overlapping expression patterns suggest that ecdysone signaling does not regulate Mamo and therefore cannot control the specification of α'β' neurons. Furthermore, expression of *UAS-EcR-RNAi* or mutants for *usp* do not lead to the loss of α'β' neurons. We note that our *usp* results contradict the loss of α'β' neuron reported by [@bib50] in *usp* clones. However, we could see α'β' neurons in these clones based on the morphology of these neurons but the remodeling defect of γ neurons makes α'β' neurons difficult to identify. Nevertheless, ecdysone might still function later during α'β' differentiation, particularly during pupation when all mushroom body neurons express EcR.

We and Marchetti and Tavosanis have both shown that expression of *UAS-EcR-DN* leads to the loss of α'β' neurons by acting in mushroom body neurons but not in neuroblasts ([@bib50]). However, EcR must be first be expressed in the target cells of interest in order to make any conclusions about ecdysone function using *UAS-EcR-DN*. Since we cannot detect EcR protein in Mamo^+^ cells at L3, but expressing *UAS-EcR-DN* inhibits Mamo in those cells, we conclude that EcR-DN artifactually represses Mamo and leads to the loss of α'β' neurons. This explains why expressing *UAS-EcR-B1* does not rescue α'β' neurons in *babo* clones. However, Marchetti and Tavosanis did rescue *babo-RNAi* by expressing EcR ([@bib51]). This is likely because our experiments were performed using *babo* MARCM clones in which the loss of α'β' neurons is much more severe than with *babo-*RNAi used in their experiments ([Figure 1---figure supplement 1Q](#fig1s1){ref-type="fig"}; [@bib51]). Indeed, when we attempted to eliminate α'β' neurons using a validated *UAS-babo-RNAi* construct ([@bib5]), γ neurons did not remodel but there was only a minor (but significant) decrease in the number of α'β' neurons. This indicates that knocking-down *babo* with *mb-Gal4* that is only weakly expressed in neuroblasts and newborn neurons is not strong enough to inhibit α'β' specification. Thus, we speculate that the LexA line used by Marchetti and Tavosanis (*GMR26E01-LexA*) may not be a reliable reporter for α'β' neurons upon *babo* knockdown, and that it might be ecdysone sensitive later in α'β' differentiation. Since EcR expression in all mushroom body neurons at L3 may be dependent on activin signaling directly in neurons, as it is in γ neurons for remodeling ([@bib89]), expressing *UAS-EcR-B1* together with *UAS-babo-RNAi* using *OK107-Gal4* might both reduce the effectiveness of the RNAi while also allowing for the re-expression of *GMR26E01-LexA*.

Glia are a source of the activin ligand *myo*, which is temporally expressed in brain glia starting at L3 to initiate the remodeling of mushroom body γ neurons ([@bib5]) and α'β' specification ([Figure 4](#fig4){ref-type="fig"}; [@bib51]). However, knocking-down Myo from glia is not as severe as removing Babo from mushroom body neuroblasts. This might be due to incomplete knockdown of *myo* or to other sources of Myo, potentially from neurons. For example, in the vertebrate cortex, old neurons signal back to young neurons to control their numbers ([@bib58]; [@bib61]; [@bib73]; [@bib79]). It is also possible the Babo is activated by other activin ligands, including Activin and Dawdle ([@bib76]). An intriguing hypothesis is that the temporal expression of *myo* in glia beginning at mid-L3 is induced by the attainment of critical weight and rising ecdysone levels. It would be interesting to determine whether blocking ecdysone signaling in glia leads to the loss of α'β' specification, similar to how blocking ecdysone reception in astrocytes prevents γ neuron remodeling ([@bib23]).

Conserved mechanisms of temporal patterning {#s3-4}
-------------------------------------------

It is well established that extrinsic cues play important roles during vertebrate neurogenesis, either by regulating temporal competence of neural stem cells or by controlling the timing of temporal identity transitions (reviewed in [@bib33]). Competence changes mediated by extrinsic cues were demonstrated in classic heterochronic transplantation studies that showed that young donor progenitors produce old neuronal types when placed in older host brains ([@bib17]; [@bib21]; [@bib53]). Recent studies show that the reverse is also true when old progenitors are placed in a young environment ([@bib56]).

Mechanisms of intrinsic temporal patterning are also conserved ([@bib1]; [@bib20]; [@bib25]; [@bib35]; [@bib52]; [@bib62]). For example, vertebrate retinal progenitor cells use an intrinsic tTF cascade to bias young, middle, and old retinal fates ([@bib20]; [@bib47]; [@bib52]). Two of the factors (Ikaros and Casz1) used for intrinsic temporal patterning are orthologs to the *Drosophila* tTFs Hb and Cas. tTF series might also exist in cortical radial glia progenitors and even in the spinal cord ([@bib16]; [@bib22]; [@bib48]; [@bib71]; [@bib72]). Recent results also show the importance of post-transcriptional regulation in defining either young or old cortical fates ([@bib64]; [@bib88]), which can be compared to the use of post-transcriptional regulators that are a hallmark of neuronal temporal patterning in *Drosophila* central brain neuroblasts. These studies highlight that the mechanisms driving the diversification of neuronal types are conserved.

Materials and methods {#s4}
=====================

*Drosophila* strains and MARCM {#s4-1}
------------------------------

Flies were kept on standard cornmeal medium at 25°C. For MARCM experiments, embryos were collected every 12 hr. After 24 hr, L1 larvae were placed at 37°C for 2 hr for neuroblast clones or 15 min for GMC clones. To target GMCs at L3, larvae were aged for 84 hr and then placed at 37°C for 15 min. Brains were dissected from 1 to 5 day old adults.

We used the following transgenic and mutant flies in combination or recombined in this study. {} enclose individual genotypes, separated by commas. Stock numbers refers to BDSC unless otherwise stated:

{*y, w, UAS-mCD8::GFP, hsFlp; FRTG13, tub-Gal80/CYO;; OK107-Gal4* (gift from Oren Schuldiner)}, {*hsFLP, y, w; FRTG13, UAS-mCD8::GFP* (\#5131)}, {*hsFLP, tubP-GAL80, w, FRT19A; UAS-mCD8::GFP/CyO; OK107-Gal4* (\#44407)}, {*hsFLP, y, w, UAS-mCD8::GFP; FRT82B, tubP-GAL80/TM3, Sb^1^; OK107-Gal4* (\#44408)}, {*hsFLP, y^1^, w\*, UAS-mCD8::GFP; tubP-GAL80, FRT40A; OK107-Gal4* (\#44406)}, {*UAS-EcR.B1-DeltaC655.W650A* (\#6872)}, {*y, w, FRT19A* (\#1744)}, {*FRTG13, babo^52^* (gift from Dr. Michael B. O'Connor)}, {*w; FRTG13* (\#1956)}, {*w1118; repo-Gal4/TM3, Sb^1^* (\#7415)}, {w; *GMR71G10-GAL4* (\#39604)}, {w; *GMR41C07-GAL4/TM3, Sb^1^* (\#48145)}, {*w; GMR13F02-GAL4* (\#48571)}, {*w; GMR44E04-GAL4* (\#50210)}, {*w\*; insc-Gal4^Mz1407^* (\#8751)}, {*usp^2^/FM7a* (\#31414)}, {*Met^27^, gce^2.5K^/FM7c, 2xTb^1^-RFP, sn^+^* (gift from Dr. Lynn Riddiford)}, {*y^d2^, w^1118^, ey-FLP; tai^EY11718^ FRT40A/CyO, y^+^* (DGRC \#114680)}, {*dpy^ov1^, tai^61G1^, FRT40A/CyO* (\#6379)}, {*w\*; smo^119B6^, al^1^, dpy^ov1^, b^1^, FRT40A/CyO* (\#24772)}, {*FRT82B, svp^1^/TM3* (gift from Tzumin Lee)}, {*y^1^, w\*, UAS-mCD8::GFP, Smox^MB388^, FRT19A/FM7c* (\#44384)}, {*w\*;; UAS-p35* (\#5073)}, *{y^1^, w; Mi{PT-GFSTF.1}EcR\[MI05320-GFSTF.1\]/SM6a,* (\#59823)}, {*y^1^, w\*; Pin^Yt^/CyO; UAS-mCD8::GFP* (\#5130)}, {*w\*;; UAS-EcR.B1* (\#6469)}, {*y, w;; UAS-babo-a/TM6* (gift from Dr. Michael O'Connor)}, {*UAS-Imp-RNAi* (\#34977)}, ﻿{*UAS-Imp-RM-Flag* (gift from Dr. Tzumin Lee)}, ﻿{*UAS-Syp-RNAi* (VDRC 33012, gift from Dr. Tzumin Lee)}, {*UAS-Syp-RB-HA* (gift from Dr. Tzumin Lee)}, {*y^1^, v^1^; UAS-myoglianin-RNAi* (\#31200)}, {*w\*; OK107-Gal4/In^4^, ci^D^* (\#854)}; {*w, UAS-EcR-RNAi* (\#9326)}; {*w, UAS-EcR-RNAi* (\#9327)}; {*yw*, *UAS-babo.Q302D* (\#64293)}; {*UAS-babo-RNAi* (\#44400)}.

Immunohistochemistry and microscopy {#s4-2}
-----------------------------------

Fly brains were dissected in ice-cold PBS and fixed for 15--20 min in 4% Formaldehyde (v/w) in 1XPBS. Following a 2 hr wash in PBST (1XPBS + 0.3% Triton X-100), brains were incubated for 1--2 days in primary antibodies diluted in PBST, followed by overnight with secondary antibodies diluted in PBST. After washes, brains were mounted in Slowfade (Life Technologies) and imaged on either a Leica SP5 or SP8 confocal. Images were processed in Fiji and Adobe Illustrator (CC18).

We used the following antibodies in this study: sheep anti-GFP (1:500, Bio-Rad ﻿\#4745--1051; RRID:[AB_619712](https://scicrunch.org/resolver/AB_619712)), mouse anti-Trio (1:50, DSHB \#9.4A anti-Trio; RRID:[AB_528494](https://scicrunch.org/resolver/AB_528494)), guinea pig anti-Mamo (1:200, this study, Genscript), mouse anti-FasII (1:50, DSHB \#1D4 anti-Fasciclin II; RRID:[AB_528235](https://scicrunch.org/resolver/AB_528235)), rat anti-Imp (1:200, this study, Genscript), rabbit anti-Syp (1:200, this study, Genscript), guinea pig anti-Dpn (1:1000, Genscript), rabbit anti-FasII (1:50, this study, Genscript), mouse anti-EcR-B1 (1:20, DSHB \#AD4.4(EcR-B1); RRID:[AB_528215](https://scicrunch.org/resolver/AB_528215)), mouse anti-Dac2-3 (1:20, DSHB \#mAbdac2-3; RRID:[AB_528190](https://scicrunch.org/resolver/AB_528190)), guinea pig anti-Chinmo (1:200, this study, Genscript), rat anti-Chinmo (1:200, gift from Dr. Cedric Maurange), ﻿rat anti-DNcad (1:20, DSHB \#DN-Ex \#8; RRID:[AB_528121](https://scicrunch.org/resolver/AB_528121)), donkey anti-sheep Alexa 488 (1:500, Jackson ImmunoResearch \#713-545-147; RRID:[AB_2340745](https://scicrunch.org/resolver/AB_2340745)), ﻿donkey anti-mouse Alexa 555 (1:400, Thermo Scientific ﻿\#A-31570; RRID:[AB_2536180](https://scicrunch.org/resolver/AB_2536180)), donkey anti-rabbit Alexa 555 (1:400, Thermo Scientific \#A-31572; RRID:[AB_162543](https://scicrunch.org/resolver/AB_162543)), donkey anti-rat Alexa 647 (1:400, Jackson Immunochemicals \#712-605-153; RRID:[AB_2340694](https://scicrunch.org/resolver/AB_2340694)), ﻿donkey anti-guinea pig Alexa 647 (1:400, Jackson Immunochemicals ﻿\#706-605-148; RRID:[AB_2340476](https://scicrunch.org/resolver/AB_2340476)), ﻿donkey anti-rabbit 405 (1:100, Jackson Immunochemicals ﻿\#711-475-152; RRID:[AB_2340616](https://scicrunch.org/resolver/AB_2340616)), ﻿donkey anti-rat Cy3 (1:400, Jackson Immunochemicals ﻿\#712-165-153; RRID:[AB_2340667](https://scicrunch.org/resolver/AB_2340667)), donkey anti-mouse 405 (1:100, Jackson Immunochemicals ﻿\#715-475-150; RRID:[AB_2340839](https://scicrunch.org/resolver/AB_2340839)).

﻿Polyclonal antibodies were generated by Genscript (<https://www.genscript.com/>). The epitopes used for each immunization are listed below.

Mamo: amino acids 467--636 of the full length protein:

MDDRLEQDVDEEDLDDDVVVVGPATAMARGIAQRLAHQNLQRLHHTHHHAQHQHSQHHHPHSQHHHTPHHQQHHTHSDDEDAMPVIAKSEILDDDYDDEMDLEDDDEADNSSNDLGLNMKMGSGGAGGGGGVDLSTGSTLIPSPLITLPSSSAAAAAAAAAAMESQRSTPHHHHHH.

Imp: amino acids 76--455 (of isoform PB) of the full length protein:

ADFPLRILVQSEMVGAIIGRQGSTIRTITQQSRARVDVHRKENVGSLEKSITIYGNPENCTNACKRILEVMQQEAISTNKGEICLKILAHNNLIGRIIGKSGNTIKRIMQDTDTKITVSSINDINSFNLERIITVKGLIENMSRAENQISTKLRQSYENDLQAMAPQSLMFPGLHPMAMMSTPGNGMVFNTSMPFPSCQSFAMSKTPASVVPPVFPNDLQETTYLYIPNNAVGAIIGTRGSHIRSIMRFSNASLKIAPLDADKPLDQQTERKVTIVGTPEGQWKAQYMIFEKMREEGFMCGTDDVRLTVELLVASSQVGRIIGKGGQNVRELQRVTGSVIKLPEHALAPPSGGDEETPVHIIGLFYSVQSAQRRIRAMML.

Syp: amino acids 35-231(of isoform PA) of the full length protein:

MAEGNGELLDDINQKADDRGDGERTEDYPKLLEYGLDKKVAGKLDEIYKTGKLAHAELDERALDALKEFPVDGALNVLGQFLESNLEHVSNKSAYLCGVMKTYRQKSRASQQGVAAPATVKGPDEDKIKKILERTGYTLDVTTGQRKYGGPPPHWEGNVPGNGCEVFCGKIPKDMYEDELIPLFENCGIIWDLRLMM.

FasII: amino acids 770--873 (of isoform PA) of the full length protein:

MHHHHHHDLLCCITVHMGVMATMCRKAKRSPSEIDDEAKLGSGQLVKEPPPSPLPLPPPVKLGGSPMSTPLDEKEPLRTPTGSIKQNSTIEFDGRFVHSRSGEIIGKNSAV.

Chinmo: amino acids 494--604 (of isoform PF) of the full length protein:

MLNVWNATKMNNKNSVNTADGKKLKCLYCDRLYGYETNLRAHIRQRHQGIRVPCPFCERTFTRNNTVRRHIAREHKQEIGLAAGATIAPAHLAAAAAASAAATAAAS NHSPHHHHHH.

Cell counts quantification {#s4-3}
--------------------------

All confocal images were taken with a step size of three microns. Using Fiji, each image was cropped to limit the area to a region containing mostly mushroom body cell bodies. In all cases, GFP^+^ cells were manually counted. To count α'β' neurons, images were split into their individual channels and the channel containing Mamo staining was automatically binarized to account for weak and strong Mamo expression using either Default or RenyiEntropy thresholding. Binarized images were processed further using the Watershed method to differentiate between contacting cells. The number of particles (*i.e.,* strong Mamo cells) measuring between 50-infinity squared pixels were automatically counted using the Analyze Particles function and a separate channel containing bare outlines of the counts was produced and inverted. This method automatically produced the total number of strong Mamo^+^ cells. Individual channels were then remerged. Outlines drawn from the Analyze Particles function that overlapped with GFP^+^ cells were defined as α'β' neurons within a clone. In the eight cases where two mushroom body neuroblasts were labeled in a single hemisphere (wildtype:1; *babo*, *UAS-EcR*: 3; *babo*, *UAS-Syp*: 2), the total number of α'β' neurons within clones was divided by 2.

Imp and Syp fluorescence quantification {#s4-4}
---------------------------------------

All brains used for quantifying Imp and Syp fluorescence values in *babo* or *UAS-EcR-DN* mutants were prepared together. Additionally, all images used for quantification were imaged using the same confocal settings for each channel. Fluorescence measurements were made in Fiji. Values for Imp and Syp were measured within the same hand-drawn area encompassing the entire neuroblast from a single z-slice.

Statistics {#s4-5}
----------

Statistical tests were performed in Excel or R. The exact tests used are reported in the figure legends. In all cases, whisker plots represent the minimum value (bottom whisker), first quartile (bottom of box to middle line), inclusive median (middle line), third quartile (middle line to top of box) and maximum value (top whisker). The 'x' represents the average value. Outliers are 1.5 times the distance from the first and third quartile. Reported are averages ± standard error of mean (SEM).
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**Acceptance summary:**

The generation of neuronal diversity often requires progenitors to produce distinct neural subtypes over time. Previous work in *Drosophila* has shown that temporal transcription factors function as a progenitor intrinsic \"clock\" to sequentially generate different neural subtypes. Here, Rossi and Desplan show there is also a progenitor extrinsic signaling pathway that is also required to generate temporally-distinct neural subtypes. Importantly, they document cross-talk between the intrinsic and extrinsic pathways required to generate neuronal diversity. This provides a novel paradigm for considering *Drosophila* and mammalian neural cell fate specification.

**Decision letter after peer review:**

Thank you for submitting your article \"Extrinsic Activin signaling cooperates with an intrinsic temporal program to increase mushroom body neuronal diversity\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Chris Q Doe as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by K VijayRaghavan as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is \"in revision at *eLife*\". Please let us know if you would like to pursue this option.

Summary:

This manuscript from Rossi and Desplan addresses the integration of intrinsic and extrinsic cues in the specification of temporal identity within the *Drosophila* mushroom body neuroblast (MBNB) lineages, which sequentially produce four subtypes of neurons: γ, α'/β', p.α'/β' and a/b. The mechanisms generating neuronal diversity are important and of general interest; the integration of progenitor intrinsic and extrinsic cues is relatively novel.

The manuscript builds on closely related work from Marchetti and Tavosanis (2017, 2019). Both labs show that the TGFb signaling pathway is required for α'/β' adult neuron identity, but via highly divergent mechanisms. Marchetti proposes TGFb drives expression of the steroid hormone receptor EcR which is required for consolidating α'/β' fate in adult neurons (but not for their specification); when the pathway is compromised, α'/β' neurons switch to a later-born pioneer.α'/β' fate. In contrast, Rossi proposes TGFb represses the intrinsic temporal factor Imp in neuroblasts, with low Imp levels specifying α'/β' identity; when the pathway is compromised, the α'/β' neurons switch to an earlier-born high Imp γ neuron identity.

All reviewers felt the current manuscript contained well-designed experiments, convincing figures, and that the logical flow made it easy to follow. All reviewers felt the paper was appropriate for *eLife* based on the journal\'s policy of reviewing papers where an overlapping paper has been recently published with the goals of (a) independently replicating results, or (b) correct previous findings. Nevertheless, all reviewers felt this manuscript failed to resolve conflicts in data and interpretation with prior papers, particularly the role of EcR and the difference between specification and consolidation. Thus, the large majority of comments below ask for additional experiments or text changes to reconcile the two sets of results.

Essential revisions:

1\) The role of EcR signaling. This is central to the Marchetti model, but excluded from the Rossi model. The authors should put more effort into resolving the different conclusions on EcR signaling in specifying α'/β' neuron identity. Some experiments give similar results (e.g. EcR-DN expression reduces α'/β' neurons), however, the global interpretation is quite different, which makes the current work more significant. Unfortunately, the differences in interpretation are not explained or discussed, which leave the reader in a perplexed mood, because the main conclusions of the two papers do not seem compatible.

a\) Marchetti et al. show that TGFb signaling induces expression of EcRB1, and that forced expression of EcRB1 can rescue a *babo* mutant phenotype; the α'/β' neurons are restored. This is strong evidence for the role of EcRB1 in TGFb specification of α'/β' identity. The Rossi manuscript also shows that the TGFb pathway is required for α'/β' fate, but independent of EcR. How can these opposing results be reconciled?

b\) The fact that the α\'/β\' marker Mamo is still expressed when EcR-RNAi is mis-expressed does not necessarily means that ecdysone signaling is not required for α'β' specification. It is well-documented that EcRDN and EcR-RNAi mis-expression can lead to opposite phenotypes (PMID: 16354717, 25126791, 28394252). Indeed, EcR-DN prevents activation of ecdysone signaling induced by the production of ecdysone, but leaves intact the repressive ability of unbound EcR. In contrast, EcR-RNAi prevents both activation of ecdysone signaling and the repressive role of EcR in absence of ecdysone. One possibility is that Mamo, in the absence of ecdysone is repressed in neurons by unbound EcR, and that ecdysone signaling activates Mamo expression by relieving the EcR-mediated repression. If this is true, one may see precocious expression of Mamo in early L3 upon EcR-RNAi expression (similar to the UAS-babo-Act phenotype). The authors should investigate this to clarify the point.

c\) Major differences are observed in the experiments removing the EcR co-factor Usp. Marchetti, 2017 showed *usp* clones lack α'/β' neurons; here *usp* clones show normal α'/β' neurons. Are both labs using the same reagent? Can the authors show that their *usp* mutant clones lack USP protein?

2\) The primary novel conclusion in the present manuscript is that Myo signaling specifies α'/β' neurons via regulating Imp levels, but the data to support this is rather slim. The only supportive data is the elevated Imp level in *babo* mutant neuroblast.

a\) Importantly, they failed to rescue the α'/β' neuron identity by forced expression of Imp in *babo* mutant clones. How is this consistent with their model?

b\) Furthermore, the authors show that overexpression of EcR-DN leads to suppression of α'/β' neuron specification (Figure 6E), but in the same figure, they also show that the Imp levels are not changed in the neuroblasts (Figure 6H and J), which suggests that the changing Imp levels in neuroblasts may not be required to change α'/β' neuron specification.

c\) Also, the authors demonstrate that TGFb signaling intersects with the Imp/Syp temporal patterning system by showing that Imp remains expressed at higher levels in MB NBs that are mutant for babo. The maintenance of higher levels of Imp is supposed to be sufficient to prevent expression of Mamo. Since Chinmo is regulated by the Imp/Syp module and that Mamo is activated by low levels of Chinmo, one should expect high levels of Chinmo to be maintained in late larval neurons produced in the *babo* mutant context. Is this observed? The Marchetti study says that they don\'t see any obvious changes.

d\) If TGFb signaling is indeed required to terminate the first temporal window and activate the second temporal window then, γ neurons should still be generated in late L3 MB neuroblasts that are mutants for babo. As this is such a critical point in their model, the authors should do a precise time course to determine how long MB neuroblasts continue to generate γ neurons when mutant for *babo* (compared to wt). This should be checked using Abrupt as a marker for γ neurons, which seems to be more specific than Trio.

e\) Related to the previous point: the evidence that TGFb signaling intersects with progression of the Imp/Syncrip temporal patterning system remains thin (slightly higher levels of Imp in late larval and pupal MB neuroblasts that are mutant for babo). Further evidence is needed, to confirm that TGFb signaling is responsible for creating a novel temporal window, as opposed to a role in fate consolidation as proposed by Marchetti.

f\) Finally, they showed that either knockdown or overexpression of Imp using mb-GAL4 leads to loss of Mamo, a marker for α'/β' neurons. mb-GAL4 is strongly expressed in mushroom body neurons and is weakly expressed in neuroblasts, so the manipulation of Imp level is not only done in neuroblasts but also in neurons, and thus it is possible that the Imp, which appears to also be expressed in post mitotic neurons (Figure S3D), is actually required in already specified α'/β' neurons to maintain their identity, consistent with the Marchetti model.

3\) Marchetti show that TGFb signaling acts in neuroblasts, but is not required for α'/β' neuron specification during larval stages, nor for the normal levels of the early temporal factors Chinmo and Abrupt. Rather, TGFb signaling is required to stabilize/consolidate α'/β' identity in adults. In this work, loss of TGFb signaling increases Imp temporal identity levels, which should alter Chinmo and Abrupt levels. Can you resolve this discrepancy?

4\) The authors state in the text and show in the final model figure that loss of TGFb signaling leads to a loss of mid-born α'/β' neurons (well supported by multiple experiments) and an expansion of early-born γ neurons, \"although not significantly\". Either more n\'s need to be added to (potentially) reveal significance, or the figure and conclusions need to be toned down. Showing a doubling of γ neurons in the model figure when they are \'not significantly\' increased is a stretch.

5\) Marchetti observe EcR-B1 expression in all α'β' neurons. This manuscript shows EcR-B1 is not expressed in Mamo+ α'/β' neurons. This is a puzzle that should be resolved. Perhaps by checking that C305-GAL4 and Mamo are expressed in the same set of mushroom body neurons in late L3?

6\) An important point that remains unresolved and that has not been investigated nor discussed is what controls the temporal expression of Myo in glia after critical weight is achieved at mid-larval stage. An attractive hypothesis is that it is induced by the mid-L3 pulses of ecdysone. This can be easily investigated using available Myo-GAL4-driven GFP expression lines and looking at mid 3rd instar. Resolving this point would make the whole study more attractive, and different from the Marchetti one.

7\) Marchetti shows loss of TGFb signaling transforms α'/β' neurons to later-born pioneer α'/β' neurons; this work shows that loss of TGFb signaling transforms α'/β' neurons to earlier-born γ neurons. Please discuss.

10.7554/eLife.58880.sa2

Author response

> Essential revisions:
>
> 1\) The role of EcR signaling. This is central to the Marchetti model, but excluded from the Rossi model. The authors should put more effort into resolving the different conclusions on EcR signaling in specifying α'/β' neuron identity. Some experiments give similar results (e.g. EcR-DN expression reduces α'/β' neurons), however, the global interpretation is quite different, which makes the current work more significant. Unfortunately, the differences in interpretation are not explained or discussed, which leave the reader in a perplexed mood, because the main conclusions of the two papers do not seem compatible.

To make sure that the interpretation of the differences is clear, we have rewritten and added additional text to explain the differences between our work and the work from Marchetti and Tavosanis. We exclude EcR from our model because our data suggest that only EcR-DN, but not EcR knockdown or *usp* mutants, blocks α'β' specification. EcR-DN blocks α'β' specification by inhibiting Mamo. Obviously, EcR must be expressed in these cells for EcR-DN to demonstrate function. However, EcR is not expressed in Mamo+ cells that are destined to become α'β' neurons during L3. In addition, Mamo starts being expressed in presumptive α'β' neurons from mid-L3 while EcR is only activated later at wandering L3, another point that we highlight in the text. Following this logic, we conclude that EcR-DN must artificially repress Mamo during α'β' specification. We speculate that Mamo may be regulated by EcR in other contexts and that this regulation is hijacked by expressing *UAS-EcR-DN* with *OK107-Gal4*.

> a\) Marchetti et al. show that TGFb signaling induces expression of EcRB1, and that forced expression of EcRB1 can rescue a babo mutant phenotype; the α'/β' neurons are restored. This is strong evidence for the role of EcRB1 in TGFb specification of α'/β' identity. The Rossi manuscript also shows that the TGFb pathway is required for α'/β' fate, but independent of EcR. How can these opposing results be reconciled?

We agree that this is a main difference between the two studies and have addressed it by adding a new result and text in our Results and Discussion sections. The most parsimonious explanation is that the differences in the results are a consequence of methods used. First, we failed to rescue *babo* mutant clones while they rescued a *babo-RNAi*. *babo* mutant clones lead to an almost complete loss of α'β' neurons (while, in their manuscript, expressing *babo-RNAi* using *OK107-Gal4* reduces the number of α'β' neurons by about 2/3). Second, we quantified the loss of α'β' neurons in adult clones using two molecular markers (high Mamo and Trio) while they used a LexA driver (*GMR26E01-LexA*). We speculate that this LexA driver is ecdysone sensitive (indirectly). Indeed, all mushroom body neurons express EcR during the pupal stages. If Activin signaling activates EcR expression in all mature mushroom body neurons as it does in γ neurons (independent of its role in mushroom body neuroblasts), then this LexA driver may not be effectively activated late. By expressing *UAS-EcR-B1* and *babo-RNAi* together, they might rescue expression of the LexA driver. In support of this, we now show that by knocking-down *babo* with *OK107-Gal4,* that the majority of α'β' neurons are present in the adult using Mamo and Trio while g neurons do not remodel in these same brains. Therefore, we speculate that *GMR26E01-LexA* is not a reliable marker for α'β' neurons in this context.

![Representative images showing the presence of α'β' neurons based on strong Mamo (gray) and Trio (magenta) expression in adult mushroom body neurons labeled by *mb-Gal4* driving *UAS-CD8::GFP*.\
N-N'''. Images highlighting the vertical mushroom body axons. α' axons are Trio^+^ and GFP^+^. FasII (gray) labels α axons. O-O''. The majority of α'β' neurons are still present following expression of *UAS-babo-RNAi* based on strong Mamo and Trio expression. P-P'''. The vertical lobes indicate that γ neurons do not remodel (FasII^+^/Trio^+^/GFP^+^) and that α'β'neurons are still present (α' lobe that is FasII^-^/Trio^+^/GFP^+^) following *UAS-babo-RNAi* expression. Q. Quantification of the number of α'β' neurons following expression of *UAS-babo-RNAi* (n=6) compared to wildtype controls (n=6). A two-sample, two-tailed t-test was performed.](elife-58880-resp-fig1){#sa2fig1}

> b\) The fact that the α'/β' marker Mamo is still expressed when EcR-RNAi is mis-expressed does not necessarily means that ecdysone signaling is not required for α'β' specification. It is well-documented that EcRDN and EcR-RNAi mis-expression can lead to opposite phenotypes (PMID: 16354717, 25126791, 28394252). Indeed, EcR-DN prevents activation of ecdysone signaling induced by the production of ecdysone, but leaves intact the repressive ability of unbound EcR. In contrast, EcR-RNAi prevents both activation of ecdysone signaling and the repressive role of EcR in absence of ecdysone. One possibility is that Mamo, in the absence of ecdysone is repressed in neurons by unbound EcR, and that ecdysone signaling activates Mamo expression by relieving the EcR-mediated repression. If this is true, one may see precocious expression of Mamo in early L3 upon EcR-RNAi expression (similar to the UAS-babo-Act phenotype). The authors should investigate this to clarify the point.

We are aware that EcR-DN and EcR-RNAi have different modes of action. Although the suggestion by the reviewer is logical, the underlying assumption is that EcR is normally expressed in Mamo+ cells. We have shown that this is not the case, as EcR and Mamo do not overlap. If the above model was correct (i.e., unbound EcR inhibits Mamo), then EcR must be expressed in Mamo+ cells, which it is not. Furthermore, this model would require that EcR be expressed before Mamo in mushroom body neurons during development and again, this is not the case since Mamo is expressed in presumptive α'β' neurons from mid-L3 while EcR can only be detected later at wandering L3. We have added text to our Results and Discussion section highlighting this point.

> c\) Major differences are observed in the experiments removing the EcR co-factor Usp. Marchetti, 2017 showed usp clones lack α'/β' neurons; here usp clones show normal α'/β' neurons. Are both labs using the same reagent? Can the authors show that their usp mutant clones lack USP protein?

We initially reported clones of the *usp2* (amorphic) allele while they used (hypomorphic) *usp3* allele. We therefore made *usp3* mutant clones, which we now report also contain α'β' neurons (and unpruned γ neurons) (See Figure 6---figure supplement 1C-C'''). The difference in interpretation may be due to the fact that in the *usp* clones, γ neurons do not remodel, which can make identifying α'β' neurons based on morphology alone quite difficult. Nonetheless, from the single image published in Marchetti and Tavosanis' paper, it is clear that their *usp* mutant clones induced at L1 contain α'β' neurons marked by GFP+/FasII- are present. The reviewer asked us to show that our *usp* mutant clones lack Usp protein: all of our *usp* neuroblasts clones induced at L1 contain unpruned γ neurons (see Figure 6F, Figure 6---figure supplement 1C-C'''), demonstrating that *usp* is indeed missing. We have added text to our Discussion describing our interpretation of the Marchetti and Tavosanis results. We have communicated with these authors multiple times to explain our interpretation.

> 2\) The primary novel conclusion in the present manuscript is that Myo signaling specifies α'/β' neurons via regulating Imp levels, but the data to support this is rather slim. The only supportive data is the elevated Imp level in babo mutant neuroblast.

We agree that the conclusion that Activin signaling interacts with the intrinsic Imp and Syp temporal gradients is the most novel concept in our paper. Our work not only confirms that Activin signaling is necessary to specify α'β' neurons but also shows how two different temporal mechanisms interact to increase neuronal diversity.

We believe that we provide a very strong proof that Imp levels in mushroom body neuroblasts are regulated by Activin signaling: Imp levels in mutant neuroblast clones are very significantly increased and this was internally controlled with the levels of Imp in neighboring wildtype neuroblasts. Furthermore, this is further supported by the high levels of Chinmo in *babo* clones at the time α'β' neurons should be produced (see image S3C). We feel that these are more than slim evidence.

> a\) Importantly, they failed to rescue the α'/β' neuron identity by forced expression of Imp in babo mutant clones. How is this consistent with their model?

We guess the reviewers meant to comment on our rescue of *babo* clones by reducing *Imp* levels, which did not rescue α'β' specification (Figure 5---figure supplement 1). However, we show (and it is well documented) that *Imp-RNAi* expression leads to the loss of α'β' neurons and our results are entirely consistent with our proposed model that low imp (but not 'no Imp') is required for α'β' specification. Given our model, we think that reducing the levels of *Imp* specifically at L3 in *babo* mutant clones (but still inducing clones at L1) might rescue the loss of α'β' neurons. This would require us to perform long and technically difficult experiments that were in progress but were interrupted by the lockdown. We now include text in our Discussion addressing this experiment and our model.

> b\) Furthermore, the authors show that overexpression of EcR-DN leads to suppression of α'/β' neuron specification (Figure 6E), but in the same figure, they also show that the Imp levels are not changed in the neuroblasts (Figure 6H and J), which suggests that the changing Imp levels in neuroblasts may not be required to change α'/β' neuron specification.

As described above, we suggest that EcR-DN blocks α'β' specification by acting late in postmitotic neurons, not in neuroblasts. We showed that expressing EcR-DN in neuroblasts (with *Insc-Gal4*) does not inhibit α'β' specification (Figure 6M). Thus, Imp levels in neuroblasts should not be affected by expressing EcR-DN: Imp (and Syp) levels are inherited by neurons at birth, which is where these RNA-binding proteins act to regulate neuronal specification. In addition, EcR is not expressed in mushroom body neuroblasts or newborn postmitotic neurons (Mamo+), explaining why ecdysone signaling can only act in older postmitotic neurons. As explained above, EcR-DN acts by artificially inhibiting Mamo in newborn neurons. We have added text to our Results section highlighting this point.

> c\) Also, the authors demonstrate that TGFb signaling intersects with the Imp/Syp temporal patterning system by showing that Imp remains expressed at higher levels in MB NBs that are mutant for babo. The maintenance of higher levels of Imp is supposed to be sufficient to prevent expression of Mamo. Since Chinmo is regulated by the Imp/Syp module and that Mamo is activated by low levels of Chinmo, one should expect high levels of Chinmo to be maintained in late larval neurons produced in the babo mutant context. Is this observed? The Marchetti study says that they don\'t see any obvious changes.

We agree with the reviewers that our model indicates that Chinmo levels should be higher in *babo* mutant neurons at L3. We had done experiments to test this and were now able to analyze them and they are now included in Figure 2---figure supplement 1C-C'''. The results indicate that Chinmo levels are indeed higher in mutant neurons while they are low in the adjacent wildtype neurons.

> d\) If TGFb signaling is indeed required to terminate the first temporal window and activate the second temporal window then, γ neurons should still be generated in late L3 MB neuroblasts that are mutants for babo. As this is such a critical point in their model, the authors should do a precise time course to determine how long MB neuroblasts continue to generate γ neurons when mutant for babo (compared to wt). This should be checked using Abrupt as a marker for γ neurons, which seems to be more specific than Trio.

We show that Activin signaling is not absolutely required to terminate the first temporal window: Imp levels still decline and Syp levels still increase through time (although at a significantly lower pace) independently of Activin signaling (Figure 2---figure supplement 1J-J'). We attempted to test whether there was an increase in the number of γ neurons as this is an important component of our model but could only demonstrate a trend upwards in the adult, likely because the timing of clone induction dramatically affects variability of the number of γ neurons, while it does not affect later time windows. Unfortunately, a γ specific marker at L3 does not exist (e.g., Abrupt labels both γ and α'β' neurons at L3). To attempt to answer whether the γ window is maintained for longer, we now include a figure showing that Chinmo levels are higher in *babo* mutant clones compared to surrounding wildtype neurons at wandering L3 (Figure 2---figure supplement 1C-C'''). These mutant neurons do not express Mamo but wildtype neurons do.

> e\) Related to the previous point: the evidence that TGFb signaling intersects with progression of the Imp/Syncrip temporal patterning system remains thin (slightly higher levels of Imp in late larval and pupal MB neuroblasts that are mutant for babo). Further evidence is needed, to confirm that TGFb signaling is responsible for creating a novel temporal window, as opposed to a role in fate consolidation as proposed by Marchetti.

In order to determine that Imp is affected by Activin signaling we made MARCM clones for *babo* and characterized the levels of Imp compared to surrounding wt neuroblasts in the same brains. This clearly demonstrated a \~1.5-fold increase in Imp levels in *babo* mutant neuroblasts, which was quantified in Figure 2D and Figure 2---figure supplement 1B ). Furthermore, our data agree with Marchetti and Tavosanis who interpret their data, like us, that Babo acts in neuroblasts and not in neurons, although they do not investigate whether Imp and/or Syp levels are altered. They do argue that the α'β' fate requires EcR signaling in neurons, i.e the two pathways would act in different cell types (neuroblasts versus neurons). Our study provides an answer to this problem as we propose that Activin signaling acts on mushroom body neuroblasts to affect Imp levels, which are inherited by newborn neurons. We have revised our text to make this point clearer.

> f\) Finally, they showed that either knockdown or overexpression of Imp using mb-GAL4 leads to loss of Mamo, a marker for α'/β' neurons. mb-GAL4 is strongly expressed in mushroom body neurons and is weakly expressed in neuroblasts, so the manipulation of Imp level is not only done in neuroblasts but also in neurons, and thus it is possible that the Imp, which appears to also be expressed in post mitotic neurons (Figure S3D), is actually required in already specified α'/β' neurons to maintain their identity, consistent with the Marchetti model.

The reviewers are correct in that Imp is expressed in neurons. In fact, the original model from Tzumin Lee argues that Imp and Syp are expressed in gradients in neuroblasts but carry out their temporal patterning function in neurons (since they are inherited). These Imp levels in neurons control Chinmo translation and thus other downstream targets. When we express *Imp-RNA* with *OK107-Gal4* (*mb-Gal4*), we are in fact lowering *Imp* in both neuroblasts and neurons. This does not change the conclusion that low Imp levels in neuroblasts, which would normally be inherited from neuroblasts into neurons, are needed for low Chinmo levels and thus for Mamo expression in α'β' neurons. Our new data show that Chinmo levels are elevated in neurons at L3 in *babo* mutant clones, which support our interpretation. Low Imp levels inherited from neuroblasts are what help define α'β' neurons with everything else occurring downstream of this temporal factor. We have added text to our Discussion that better describes how Imp and Syp levels in neuroblasts are inherited by newborn neurons to control temporal identity.

> 3\) Marchetti show that TGFb signaling acts in neuroblasts, but is not required for α'/β' neuron specification during larval stages, nor for the normal levels of the early temporal factors Chinmo and Abrupt. Rather, TGFb signaling is required to stabilize/consolidate α'/β' identity in adults. In this work, loss of TGFb signaling increases Imp temporal identity levels, which should alter Chinmo and Abrupt levels. Can you resolve this discrepancy?

It is our understanding that Marchetti and Tavosanis argue that Activin signaling at L3 leads to the expression of EcR in differentiating (but already specified) α'β' neurons. They do not provide a model for how Activin signaling in neuroblasts is transmitted to neurons leading to EcR expression but the activation of EcR must occur when ecdysone is present. Although they did stain for Chinmo in *babo* mutant clones at L3, it is unclear from this single image they show whether Chinmo levels are altered. Nonetheless, we did not check Abrupt (for which we do not have a good antibody anyway) since this marker labels both γ and α'β' neurons at L3. However, we now include data in Figure 2---figure supplement 1C'C''' that shows higher Chinmo levels and loss of Mamo in *babo* mutant neurons, which is consistent with our model that in the absence of Activin signaling, higher Imp levels (in neuroblasts) at L3 are inherited by neurons and translated into higher Chinmo levels, which leads to the loss of Mamo and of α'β' specification.

> 4\) The authors state in the text and show in the final model figure that loss of TGFb signaling leads to a loss of mid-born α'/β' neurons (well supported by multiple experiments) and an expansion of early-born γ neurons, \"although not significantly\". Either more n\'s need to be added to (potentially) reveal significance, or the figure and conclusions need to be toned down. Showing a doubling of γ neurons in the model figure when they are \'not significantly\' increased is a stretch.

We agree with the reviewers that our suggestion that there are additional γ neurons is based on indirect data (i.e., higher Chinmo levels at L3, loss of Mamo at L3, no change in the number of mushroom body neurons but a loss of α'β' neurons and significant decrease in αβ neurons). We have corrected this in our model figure (Figure 7). We have also added the word, "likely" when we suggest that additional γ neurons are produced in the text.

> 5\) Marchetti observe EcR-B1 expression in all α'β' neurons. This manuscript shows EcR-B1 is not expressed in Mamo+ α'/β' neurons. This is a puzzle that should be resolved. Perhaps by checking that C305-GAL4 and Mamo are expressed in the same set of mushroom body neurons in late L3?

We show that EcR-B1 is not expressed in newborn Mamo+ α'β' neurons at L3. This agrees with Figure 2D of the 2017 paper from Marchetti and Tavosanis in which the majority of *c305-Gal4* neurons are EcR-B1 negative at L3. It is correct that α'β' neurons express EcR late, during early pupal stages, but at this point all mushroom body neurons express EcR, the α'β' window has closed, and αβ neurons are being specified. We also now discuss in the text that as α'β' neurons mature, they first express Mamo and then later EcR, which is another reason why EcR cannot affect Mamo expression and α'β' specification.

> 6\) An important point that remains unresolved and that has not been investigated nor discussed is what controls the temporal expression of Myo in glia after critical weight is achieved at mid-larval stage. An attractive hypothesis is that it is induced by the mid-L3 pulses of ecdysone. This can be easily investigated using available Myo-GAL4-driven GFP expression lines and looking at mid 3rd instar. Resolving this point would make the whole study more attractive, and different from the Marchetti one.

We agree that the question of what times the expression of Myo (and potentially other Activin ligands) from glia at L3 is very interesting. We highlight in the text that it has already been shown that *myo* is temporally expressed in central brain glia starting at mid-L3 (Awasaki et al., 2011). We also now include in the text the hypothesis that attainment of critical weight (and an increase in ecdysone) are responsible for this expression pattern of *myo*.

Attempting to determine whether ecdysone activates *myo* expression in glia is not straightforward, as this would require blocking EcR without using the Gal4-UAS system in glia and then combining this with Myo-Gal4 as suggested. This would require new tools and would likely lead to new avenues of research and additional questions that would go beyond the scope of this work. We plan on addressing the interaction between extrinsic cues, glia, and neuronal specification in future work.

> 7\) Marchetti shows loss of TGFb signaling transforms α'/β' neurons to later-born pioneer α'/β' neurons; this work shows that loss of TGFb signaling transforms α'/β' neurons to earlier-born γ neurons. Please discuss.

Indeed, Marchetti and Tavosanis concluded that additional pioneer-αβ neurons were born while we clearly show that the number of αβ neurons is significantly decreased, while γ neurons may increase, in *babo* mutant clones. The two interpretations are not at odds since higher than normal Imp levels during pupation might extend the window for pioneer-αβ neuron specification (since they are the first αβ neuronal type to be specified) while the majority of remaining later-born αβ will not have time to be generated before birth. This would both decrease the overall number of αβ neurons as we suggest but could also lead to an increase in the pioneer-αβ population. We have added text to our Discussion describing these possibilities.
